Grant of Warrants in Genmab A/S

Summary:  Genmab A/S' board of directors grants 188,900 warrants to employees of
the company.                                                                    


Copenhagen, Denmark; October 4, 2007 - Genmab A/S (OMX: GEN) announced today    
that on a board meeting the board decided to issue 188,900 warrants to employees
of the company as well as the company's subsidiaries. No members of the         
company's board or management were granted warrants.                            
                                                                                
The exercise price for each warrant is DKK 326.50. Each warrant entitles the    
owner to subscribe one share of nominally DKK 1. On the basis of an exercise    
price of DKK 326.50 and by application of the Black-Scholes formula, the average
value of each warrant can be calculated as DKK 135.25 based on an interest rate 
of 4.26% and the historical volatility of Genmab A/S shares calculated at       
38.18%.                                                                         
                                                                                
The warrants vest in blocks of 25% one, two, three and four years after the     
grant date, and all warrants expire at the tenth anniversary of the grant date. 
The new warrants were granted pursuant to the warrant plan adopted by the board 
on August 3, 2004. Information concerning Genmab's warrant schemes can be found 
on www.genmab.com under the heading ‘warrant scheme.'                           


About Genmab A/S                                                                
Genmab is a leading international biotechnology company focused on developing   
fully human antibody therapeutics for unmet medical needs.  Using unique,       
cutting-edge antibody technology, Genmab's world class discovery and development
teams have created and developed an extensive pipeline of products for potential
treatment of a variety of diseases including cancer and autoimmune disorders.   
As Genmab advances towards a commercial future, we remain committed to our      
primary goal of improving the lives of patients who are in urgent need of new   
treatment options.  For more information on Genmab's products and technology,   
visit www.genmab.com.                                                           

This press release contains forward looking statements. The words “believe”,    
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify    
forward looking statements. Actual results or performance may differ materially 
from any future results or performance expressed or implied by such statements. 
The important factors that could cause our actual results or performance to     
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical   
trials including unforeseen safety issues, uncertainties related to product     
manufacturing, the lack of market acceptance of our products, our inability to  
manage growth, the competitive environment in relation to our business area and 
markets, our inability to attract and retain suitably qualified personnel, the  
unenforceability or lack of protection of our patents and proprietary rights,   
our relationships with affiliated entities, changes and developments in         
technology which may render our products obsolete, and other factors. Genmab is 
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to      
actual results, unless this is required by law.                                 

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);  
HuMax-EGFr(TM); HuMax-Inflam(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);
HuMax-ZP3(TM); and UniBody(TM) are all trademarks of Genmab A/S.                

Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M: 
+45 25 27 47 13, E: hth@genmab.com                                              
                                                                                
Stock Exchange Release no. 47/2007                                              

###